Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Neutrophil-to-Lymphocyte Ratio and Outcomes in Patients Admitted for Acute Heart Failure (As Seen in the BLAST-AHF, Pre-RELAX-AHF, and RELAX-AHF Studies).
Journal: The American journal of cardiology
Published: March 16, 2022
Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial.
Journal: European journal of heart failure
Published: May 27, 2020
Effects of serelaxin in patients admitted for acute heart failure: a meta-analysis.
Journal: European journal of heart failure
Published: September 11, 2019
Translation of Cardiac Myosin Activation with 2-deoxy-ATP to Treat Heart Failure via an Experimental Ribonucleotide Reductase-Based Gene Therapy.
Journal: JACC. Basic to translational science
Published: May 30, 2017
Cardiac Myosin Activation with Gene Therapy Produces Sustained Inotropic Effects and May Treat Heart Failure with Reduced Ejection Fraction.
Journal: Handbook of experimental pharmacology
Published: September 04, 2016
Recombinant human relaxin versus placebo for cervical ripening: a double-blind randomised trial in pregnant women scheduled for induction of labour.
Journal: BMC pregnancy and childbirth
Published: January 16, 2016
Challenges in acute heart failure clinical management: optimizing care despite incomplete evidence and imperfect drugs.
Journal: Critical pathways in cardiology
Published: February 14, 2015
Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial.
Journal: The Journal of clinical endocrinology and metabolism
Published: February 10, 2015
Ribonucleotide reductase-mediated increase in dATP improves cardiac performance via myosin activation in a large animal model of heart failure.
Journal: European journal of heart failure
Published: December 31, 2014
Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial.
Journal: Lancet (London, England)
Published: November 13, 2012
Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes.
Journal: Journal of the American College of Cardiology
Published: October 28, 2012
Last Updated: 09/26/2026